Gilead Sciences: Who’s Frustrated Now?

Last month, I urged investors to stay away from Gilead Sciences ( GILD ), arguing that it had, in effect, become a value trap (even if I didn't use those exact words. The bearish call was born, in part, from my own frustration with the stock, which had been one of my worst picks last year. I'm not the only one that's frustrated with Gilead, however. Barclay s analyst Geoff Meacham and team note that "investors seem increasingly more frustrated" with not only Gilead, but with Alexion Pharmaceuticals ( ALXN ) and Biogen ( BIIB ) as well. They explain: